Pfizer Inc. (PFE) Rating Reiterated by Argus
Pfizer Inc. (NYSE:PFE)‘s stock had its “buy” rating restated by Argus in a research note issued to investors on Tuesday. They presently have a $39.00 price objective on the biopharmaceutical company’s stock. Argus’ price objective suggests a potential upside of 15.80% from the company’s current price.
Other research analysts have also recently issued reports about the stock. Sanford C. Bernstein restated an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Jefferies Group reiterated a “buy” rating and issued a $42.00 target price (up from $41.00) on shares of Pfizer in a research note on Tuesday, June 14th. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 target price on the stock. in a research note on Tuesday, June 28th. Citigroup Inc. reiterated a “neutral” rating and issued a $37.00 target price on shares of Pfizer in a research note on Wednesday, August 3rd. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $34.00 target price on shares of Pfizer in a research note on Tuesday, August 2nd. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $38.78.
Shares of Pfizer (NYSE:PFE) traded up 0.12% on Tuesday, hitting $33.72. 20,599,432 shares of the stock traded hands. Pfizer has a 52 week low of $28.25 and a 52 week high of $37.39. The stock has a market cap of $204.53 billion, a price-to-earnings ratio of 29.89 and a beta of 0.86. The stock has a 50 day moving average price of $34.44 and a 200-day moving average price of $34.14.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. During the same period in the previous year, the company earned $0.56 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer will post $2.46 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.56%. Pfizer’s dividend payout ratio (DPR) is 95.24%.
Large investors have recently made changes to their positions in the stock. Bloom Tree Partners LLC purchased a new stake in shares of Pfizer during the first quarter valued at $35,682,000. BlackRock Group LTD boosted its stake in shares of Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock valued at $1,762,838,000 after buying an additional 3,154,116 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock valued at $1,864,446,000 after buying an additional 9,005,107 shares during the last quarter. NN Investment Partners Holdings N.V. purchased a new stake in shares of Pfizer during the first quarter valued at $242,144,000. Finally, BlackRock Fund Advisors boosted its stake in shares of Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock valued at $2,741,378,000 after buying an additional 1,403,646 shares during the last quarter. 69.65% of the stock is owned by institutional investors.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.